Wegovy vs. Zepbound: Which GLP-1 Is Right for Your Weight Loss Journey?

The landscape of medical weight loss has been transformed by GLP-1 receptor agonist medications, and two drugs have emerged at the forefront of this revolution: Wegovy (semaglutide) and Zepbound (tirzepatide). Both are FDA-approved injectable medications that produce remarkable weight loss results far exceeding what was previously possible with traditional approaches. But they're not identical, and understanding the differences—in mechanism, efficacy, side effects, and cost—can help you and your provider determine which option may be best suited to your individual needs. Here's a comprehensive, evidence-based breakdown of these two medications.

Mechanism of Action: One vs. Two Hormonal Targets

The core pharmacological difference between these medications lies in how many hormone receptors they target.

Wegovy (semaglutide) is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone released from the gut after eating. It stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon (which raises blood sugar), slows gastric emptying, and—crucially for weight loss—acts on the brain's appetite and satiety centers to reduce hunger and food intake. Semaglutide is a synthetic analog of human GLP-1 with a half-life extended to approximately one week, allowing for once-weekly dosing.

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist—the first in its class. In addition to activating GLP-1 receptors (the same target as semaglutide), tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another incretin hormone involved in insulin secretion, fat storage regulation, and potentially additive effects on appetite and energy expenditure. This dual mechanism is believed to contribute to tirzepatide's superior weight loss outcomes observed in clinical trials.

Head-to-Head Efficacy: The Data

Both medications have demonstrated exceptional weight loss results in large clinical trials, substantially outperforming previous pharmacological options:

• Wegovy (STEP 1 trial): Participants lost an average of approximately 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. Nearly 70% of participants lost more than 10% of body weight.
• Zepbound (SURMOUNT-1 trial): At the highest dose (15 mg), participants lost an average of approximately 20.9% of body weight over 72 weeks. At the 10 mg dose, average weight loss was around 19.5%. Around 37% of participants at the highest dose lost 25% or more of body weight.
• A head-to-head comparison (the SURMOUNT-5 trial, published in 2025) confirmed that tirzepatide produced significantly greater weight loss than semaglutide directly: approximately 47% more weight lost on average.

These results suggest tirzepatide may be the more potent option for maximizing weight loss. However, it's important to recognize that individual responses vary considerably, and some people respond exceptionally well to semaglutide while having less impressive results with tirzepatide, and vice versa.

Side Effects and Tolerability

Both medications share a similar side effect profile, primarily affecting the gastrointestinal system:

Common Side Effects for Both

Nausea, vomiting, diarrhea, and constipation are the most frequently reported adverse effects with both semaglutide and tirzepatide. These effects are typically most pronounced during the dose escalation phase and tend to improve over time as the body adapts. Starting at low doses and gradually increasing—as both protocols recommend—is key to minimizing GI discomfort. Both medications also carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though this association has not been confirmed in humans. Neither is recommended for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Differences in Tolerability

Some clinical data and real-world experience suggest that tirzepatide may have slightly better overall GI tolerability than semaglutide at equivalent efficacy doses, though this is subject to individual variation. Zepbound received an FDA approval specifically for obstructive sleep apnea in addition to weight loss—an indication semaglutide does not currently have. Both may also reduce cardiovascular risk, with semaglutide having more established long-term cardiovascular outcome data (the SELECT trial demonstrated a 20% reduction in major cardiovascular events).

Cost, Insurance, and Practical Considerations

Cost is a major factor for many patients. Both medications carry high list prices (approximately $1,300–$1,600/month without insurance), and coverage varies considerably by payer:

• Commercial insurance coverage has expanded for both, particularly following cardiovascular outcome data for semaglutide
• Medicare Part D gained authority to cover obesity medications beginning in 2026, dramatically expanding access
• Manufacturer savings programs and telehealth platforms can substantially reduce out-of-pocket costs
• Compounded semaglutide and tirzepatide have been available through certain pharmacies, though FDA has indicated the drug shortage status affecting compounding eligibility may change

The "right" medication is ultimately the one that works best for your individual biology, fits your health profile, and is accessible to you. Truventa Medical's providers can assess your medical history and help determine whether Wegovy, Zepbound, or another approach is the most appropriate starting point. Explore our weight loss programs or start your consultation today.

Making the Decision: Key Questions to Discuss With Your Provider

Choosing between Wegovy and Zepbound is not a decision that should be made based on marketing or anecdote alone. Important questions to discuss with your provider include:

• Do you have type 2 diabetes? Tirzepatide has broader FDA approval across the glycemic spectrum and may offer advantages for metabolic control.
• Do you have cardiovascular disease or high cardiovascular risk? Semaglutide has more established cardiovascular outcome data at this time.
• Do you have sleep apnea? Tirzepatide (Zepbound) has an FDA indication specifically for OSA.
• What does your insurance cover? Coverage differences may significantly impact your real-world access and cost.
• Have you tried one of these medications before without success? Switching medications can sometimes produce results when one has become less effective or caused intolerable side effects.

Both Wegovy and Zepbound represent remarkable advances in the medical treatment of obesity—a condition now recognized as a chronic disease requiring long-term management. The best medication is the one that produces effective, sustainable results for your individual biology with manageable tolerability. Truventa Medical's providers are experienced with both medications and can help you navigate this decision. Start your consultation today.